Le Registre des lobbyistes
Pfizer Canada ULC
| Objets | Détails | Catégories |
|---|---|---|
|
Relations fédérales-provinciales, Marchés publics, Santé, Industrie, Propriété intellectuelle, Commerce international, Recherche et développement, Impôts et finances
|
Advocacy on the creation of the Health Emergency Readiness Canada (HERC) Agency
|
Politique ou Programme
|
|
Propriété intellectuelle, Commerce international
|
Advocacy on the proposed Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
|
Règlement, Proposition législative, Projet de loi ou résolution
|
|
Budget, Santé
|
Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
|
Subvention, Contribution ou autre avantage financier, Politique ou Programme
|
|
Santé, Commerce international
|
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
|
Politique ou Programme, Règlement, Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie, Propriété intellectuelle, Commerce international, Recherche et développement
|
Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025.
|
Proposition législative, Projet de loi ou résolution, Règlement, Politique ou Programme
|
|
Santé, Propriété intellectuelle, Commerce international
|
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
|
Règlement, Proposition législative, Projet de loi ou résolution, Politique ou Programme
|
|
Marchés publics, Santé
|
Discussions on the procurement of a COVID19 vaccine and therapy
|
Subvention, Contribution ou autre avantage financier
|
|
Santé, Industrie
|
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
|
Politique ou Programme, Règlement
|
|
Marchés publics, Santé
|
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
|
Politique ou Programme
|
|
Santé
|
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
|
Proposition législative, Projet de loi ou résolution, Règlement, Politique ou Programme
|
|
Santé
|
Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and C64, An Act to Implement pharmacare.
|
Proposition législative, Projet de loi ou résolution, Règlement, Politique ou Programme
|
|
Santé, Industrie, Commerce international
|
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
|
Politique ou Programme, Règlement
|
|
Marchés publics
|
Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts
|
Proposition législative, Projet de loi ou résolution
|
|
Santé
|
Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
|
Règlement, Politique ou Programme
|
|
Santé
|
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
|
Règlement, Politique ou Programme
|
|
Industrie
|
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
|
Politique ou Programme
|